INTRODUCTION
Neurological disorders constitute a large and increasing share of the global burden of disease. It has been reported by the World Health Organization that, although mental and neurological disorders are responsible for approx. 1 % of deaths, they account for almost 11 % of disease burden the world over. The extension of life expectancy and aging of the general populations in both developed and developing countries are likely to increase the prevalence of these diseases in the future. Yet, despite many years of research in both humans and model organisms, effective therapies exist for only a handful of neurological diseases. The mouse is a well-established and valuable system for the genetic and functional analysis of perturbations of the nervous system and significant attempts have been made over the past 5 years to generate new mouse models of disease on a large scale. A number of approaches are being pursued, from the generation of single gene knockouts and knock-ins to the systematic production of thousands of mice containing dozens of point mutations, with each method having its own advantages and limitations. Our work with the mutagenesis programme at the MRC in Harwell, U.K. has demonstrated not only that clinically relevant phenotypes can be identified using this strategy, but also that novel functions can be ascribed to known genes, providing new insights into the underlying causative factors of neurological dysfunction.
A mutant mouse menagerie
The practice of carrying out mutagenesis screens in model organisms is not confined to mice. Pioneering screens for behavioural mutants in Drosophila melanogaster began over 30 years ago [1] and have continued with great success in the fly [2] , the nematode worm Caenorhabditis elegans [3] and the zebrafish Danio rerio [4] . These lower organisms have provided the scientific community with a significant number of neurological mutants with direct relevance to human disease [5, 6] . However, the mouse has become the primary model system for the study of mammalian gene function in the context of a whole organism due to the battery of genetic manipulation techniques available, its small size and generation time, as well as the availability of the completed genomic sequence from one of the many inbred strains [7] . Yet, despite the undoubted value of mouse mutants, only 10-15 % of known genes have a corresponding mutant line.
To address this discrepancy, a number of independent large-scale chemical mutagenesis screens have been established worldwide, with the ultimate aim of systematically generating one or more mutants for every one of the 25 000 or so genes [8] [9] [10] [11] . These screens have almost exclusively used the alkylating agent ENU (N-ethyl-N-nitrosourea) as the mutagen, whereby injection into male mice at a carefully calibrated dose will cause point mutations to occur in the spermatozoa [12] . Mutant males, harbouring approx. 30-50 potentially functional gene mutations, are then bred to wild-type females of a different inbred strain. At this point, the offspring from this mating can be analysed directly for dominant mutations [13, 14] , or used for a second or third generation of breeding for the identification of inherited recessive traits [15] . Typically, each new individual mutant is characterized by a high-throughput phenotyping method targeted to a specific area of interest, such as eye defects [16] , in combination with a more general screen based on observation and simple behavioural analysis [17] . Once Mendelian inheritance and penetrance of the trait of interest has been determined, the mutation is identified by genetic mapping and the sequencing of candidate genes. However, although access to the mouse and human genomes has resulted in a significant reduction in the time taken to complete such positional cloning projects, this stage is the undoubted bottleneck of the process. Consequently, to prevent any un-mapped lines being lost, it is essential that sperm and embryos are cryopreserved from each line for future use [18] . To circumvent this problem, a more directed approach is being carried out on a smaller scale to identify recessive mutations, whereby ENU-mutated males are crossed with females carrying either chromosomal deletions [15] or inversions [19] . Not only does it significantly reduce the total number of animals required compared with a traditional recessive screen over several generations, it also greatly simplifies candidate gene identification.
A major advantage of such random mutagenesis approaches over the generation of knockouts is that no assumptions are made about the type of mutations or genes that will be identified, leading to an unbiased search for phenotypes of interest. Moreover, the single basepair substitutions generated by ENU have the potential to generate a wide range of mutations, including those that are dominant-negative (antimorphs), gain-of-function (neomorphs) as well as nulls or knockout alleles (amorphs). Considering that at the time of writing over two-thirds of 1750 genes in the Human Gene Mutation Database contain point mutations (http://archive.uwcm. ac.uk/uwcm/mg/hgmd0.html) and that approx. 75 % of known disorders in man are dominantly inherited [20] , such screens undoubtedly mirror the principal causes of human genetic disease.
Recent technological advances have improved the rapid identification of mutations from multiple samples without sequencing thereby facilitating the move towards gene-driven or sequence-targeted mutagenesis [21] . It is now possible to mutagenize thousands of ES (embryonic stem) cells with almost any mutagen and identify mutations of any given gene or target region by PCR from a library of clones [22] . Once a mutated clone has been identified, it can be used to produce live mice for phenotypic evaluation. Alternatively, DNA from the first generation of a dominant mutagenesis screen can be archived for PCR screening as above and the corresponding bank of cryopreserved sperm is then used to rederive the given mutant line [23, 24] . As in most knockout experiments, there is no guarantee of any detectable phenotype in the selected lines, although it has been calculated that a resource of only 5000 mutant lines would be required to identify at least one mutation in any given gene [24] . Whichever method is deemed the most efficient, a combination of all the above approaches will be required in tandem with knockout and transgenic technologies to reach the goal of a complete mutant mouse resource [25, 26] .
Neurological mouse mutant screens
Not only do mice and humans share common anatomical features and organization, but the sophistication of the behavioural repertoire of the mouse, including its social and emotional activity, means that even complex human neurological and psychiatric disorders can be modelled effectively. This does, however, rely on studying shared neurobiological phenotypes (or endophenotypes) or specific behavioural paradigms [27] . Attempts have been made, therefore, to apply a high-throughput approach to mouse phenotyping in concert with more directed behavioural screens to identify new neurological mutants from large scale mutagenesis projects [28, 29] . At the MGU (Mammalian Genetics Unit), Harwell, U.K., mice are put through a battery of quantitative non-invasive tests at 5 [17, 30] . The test includes measuring potential defects in grip strength, tremor and wire maneuverability, all of which may be indicative of a lesion in the nervous system. Similar protocols have been established by a majority of the major mutagenesis centres, each reflecting differing areas of interest and expertise ( Table 1 ). As part of the Harwell ENU screen, a proportion of mutants are also put through a second round of behavioural testing to investigate locomotor activity and acoustic startle response [13] . In addition, specific screens have been established to isolate mutants with circadian rhythm abnormalities [31] or anxiety-related phenotypes [32] . In all cases, a balance has to be established between the amount of information that can be gleaned from an individual screen and the speed, reproducibility and variability of the testing protocol used. Phase I of the Harwell ENU mutagenesis programme began in 1998, and more than 35 000 mice were screened for visible phenotypes [13, 33] . From the 15 000 lines that underwent the full SHIRPA screen, over 200 lines were confirmed as carrying a dominantly inherited trait (www. mgc.har.mrc.ac.uk/mutabase). Of these, 56 were classified as neurological or behavioural mutants, giving an observed phenotype detection rate of 1:28.5; much higher than, for example, a screen for deafness with a rate of 1:536. These ratios are likely to reflect the bias of the SHIRPA testing, which is specifically designed to pick up defects in sensory and autonomic function. As a general rule, the relative abundance of the various phenotypic classes reflects the ease by which they are identified. Overt abnormalities in coat colour, growth or limb morphology can be easily identified and result in oversampling within the mutant population. There is also growing evidence that the ENU mutagen itself is positionally biased within the mouse genome. Individual lines with mutations in the same gene (an allelic series) have been described for several genes, providing significantly more functional information than the corresponding knockout (reviewed in [34] ). For example, from 29 mutants mapped at Neuroscience Mutagenesis Facility of the Jackson Laboratory, three represent alleles of Scn8a and another three are Cdh23 mutant lines [15, 35] . The type of mutations identified is likely to reflect the scope of the phenotyping protocols used, although with an estimated specific locus mutation rate of 0.00108 for ENU [24, 36] , the frequency of such allelic series is significantly greater than by chance alone.
The advantages of having access to more than one mutant line representing a single gene is illustrated by the Loa (legs-at-odd-angles) and Cra1 (cramping) mutants [37] . These mice display progressive locomotor disorders and provide new models of motor neuron degeneration caused by mutations in highly conserved residues of Dnchc1 (cytoplasmic dyenin heavy chain 1), a protein vital for efficient retrograde transport in neurons. Intercrossing the two dominant mutant lines yielded compound heterozygotes that displayed the same phenotype as Loa/Loa and Cra1/Cra1 mice, confirming the two lines were allelic and presenting irrefutable corroborating evidence that the causative mutation had been isolated in each case. Both mutants exhibit pathological features similar to human neurodegenerative disorders, including Lewy body-like inclusions, although subtle differences in the localization and severity of anterior horn cell loss was observed between them. Not only has this work provided a new link between motor neuron dysfunction and retrograde transport, the allelic series will allow two independent functional domains of dynein proteins to be analysed in vivo.
The aim of our own research is to characterize further new neurological mouse mutants from the Harwell mutagenesis screen. Once a line of interest has been inheritance tested, a small cohort is taken for histological and immunohistochemical analysis. Our presumption is that, if a lesion in a specific tissue is identified, this may allow positional candidates to be prioritized for sequencing on the basis of known function or expression pattern. A set of well-established histological stains are applied to the brain, spinal cord, peripheral nerve and a range of muscle groups to identify major anatomical defects in at least two mutants and littermate controls. In addition, a panel of antibodies is used to investigate the relative abundance of a number of neuronal subpopulations. A similar, if more high-throughput approach, is carried out by TMGC (Tennessee Mouse Genome Consortium) in which five mutant phenotypes have been identified using their neurohistology protocol to date [15] . We initially selected six mutant lines from the Harwell mutagenesis project for our histological screen; four with a resting tremor and two with abnormal gaits. Two of these lines showed no detectable abnormalities, although this could be due to many reasons, such as late onset pathology or simply that the limited scope and simplicity of the screen meant that subtle lesions were missed. However, cell loss in the cerebellum was detected in an ataxic mutant and in the three remaining lines that display a resting tremor, severe hypomyelination of the sciatic nerve was observed. Subsequently, all four lines have yielded new insights into functional aspects of the mutated proteins and illustrate the power of mutagenesis screens to generate novel and scientifically valuable disease models.
NOVEL GENE FUNCTION REVEALED BY THE ATAXIC MUTANT robotic Cerebellar ataxia and the robotic mouse
Defects in balance or co-ordination and ataxia are general features of numerous neurological disorders, from those related to alcohol abuse [38] to inherited diseases such as Friedrich's ataxia [39] , SCA (spinocerebellar ataxia) [40] and lysosomal storage disorders [41, 42] . A majority of these are known to be caused by disruption of the cerebellum, the structure in the brain vital for the control of motor function and co-ordination [43] . Many cerebellar mouse mutants have been characterized over the past 30 years yielding insights into the molecular basis of the diverse range of inherited ataxias; however, there is still a large gulf in our understanding as to the underlying neurodegenerative mechanisms involved [44, 45] . The fact that gait disorders and tremor are readily observable in mice is likely to explain the relatively large number of spontaneous cerebellar mutants recognized to date. Moreover, the identification of pathological lesions is facilitated by the distinct trilaminar structure of the cerebellum [45] .
Motor defects are also common phenotypes identified in mutagenesis screens; indeed, over 50 heritable lines from the Harwell ENU screen are described as having an ataxic or unusual gait (www.mut.har.mrc.ac.uk). One of these lines was selected by us for further study, named robotic due to its jerky ataxic movements that are apparent from approx. 3 weeks of age. Mutant animals are also approx. 50 % of the size of littermate controls, and suffer from bilateral cataracts that are visible from 2 months. Our standard histological screen revealed no abnormalities in muscle, spinal cord or sciatic nerve; however, in the brain, an absence of Purkinje cells in the cerebellum was identified. Purkinje cells are large GABAergic neurones that function as the sole output from the cerebellar cortex, so it was not surprising that a loss of these cells would cause an ataxic phenotype. The cell loss occurred in a striking region-specific pattern, with the anterior of the cerebellum affected first from 8 weeks of age, followed by progressive cell death until no Purkinje cells remained in this region by 40 weeks. The posterior was significantly less affected, with lobe X spared throughout [46] (Figure 1 ). Parasagittal bands of surviving Purkinje cells were observed in transverse sections at 20 weeks of age, although this pattern was disrupted once the animals reached 10 months. Additional neurodegenerative changes preceded the onset of ataxia, including swelling of the Purkinje cell dendrites, cell bodies and focal swellings of the axons. An overall reduction in the size of the cerebellum was also observed, presumably due to a general reduction in the dendrite content of the molecular layer. This distinctive pattern of cell death has also been described for mouse models of Niemann-Pick disease types A/B (acid sphingomyelinase knockout) and C [47, 48] . In humans, these autosomal recessive lysosomal storage disorders are characterized by retarded growth and neurological abnormalities, including ataxia [41, 42] . However, no evidence for cholesterol accumulation was observed in robotic mice from both pathological and blood biochemical screens.
A genome scan was carried out to identify the chromosomal region containing the robotic mutation, followed by detailed genetic mapping. No obvious candidate genes were present within the critical region of chromosome 5, so it was necessary to generate a physical map of overlapping BACs (bacterial artificial chromosomes) for gene identification. All three genes identified in the interval were sequenced and a point mutation was isolated in Af4 [ALL (acute lymphoblastic leukaemia)-fused from chromosome 4], leading to a valine → alanine amino acid substitution. At that time, little was known about the function of AF4, although the gene had been implicated in leukaemia [49] . Consequently, to confirm that the mutation we discovered was responsible for the robotic phenotype, expression studies were carried out in the mouse brain. By in situ hybridization we revealed that Af4 was expressed specifically in Purkinje cells of the cerebellum and to a lesser degree in the hippocampus, but was not detectable in any other region of the brain. Moreover, reduced levels of expression occurred in lobes of the cerebellum less affected by the mutation in both robotic and wild-type animals. Af4 is known to be expressed in most other organs of the adult mouse [50] , although we also confirmed that transcription of the gene in the lens was detectable by RT (reverse transcriptase)-PCR. Further insight into the function of Af4 has also been gained from analysis of the knockout mouse [51] . Apart from a proportion of mutants displaying a reduced growth rate, null animals showed abnormalities in the early stages of B-and T-cell development, suggesting a role for Af4 in lymphopoiesis. Consistent with this conclusion, we also observed defects in early T-cell maturation stages in robotic mice, although distinct from the knockout phenotype. In addition, we have confirmed that neither Af4 +/− nor Af4 −/− animals show any neurological lesions or ataxia up to 12 months of age. Taken together with the expression results in the cerebellum, the evidence points towards a gain-offunction mechanism for the robotic Af4 allele.
The ALF family
AF4 is a member of the ALF (AF4/LAF4/FMR2) family of proteins that also includes the more recently identified AF5Q31 [52] [53] [54] [55] [56] . Each shares substantial regions of sequence homology at the N-and C-termini in addition to a serine-rich activation domain, a consensus bipartite nuclear localization sequence and 175-amino acid 'ALF domain' within which the robotic mutation lies [55] . The functional significance of the mutation is illustrated by the position of the amino-acid change within a run of 13 residues that share 100 % identity with all members of the ALF family [46] . Based on their conserved domains, confirmed nuclear localization and results from in vitro transactivation assays, it has been proposed that all ALF proteins act as transcription factors [57] [58] [59] . Their specific function in transcriptional activation and role in a variety of human disorders, however, remains unclear.
AF4, AF5Q31 and LAF4 are three of the 30 or so loci known to be involved in translocation events with the MLL (mixed lineage leukaemia) gene associated with human leukaemias [49, 56, 60] . The t(4;11) translocation, in which an MLL-AF4 fusion product is generated, is the most common, accounting for approx. 50 % of ALL in infants under 1 year of age [61] . It is commonly thought that the N-terminal region of MLL and the C-terminus of the partner gene encodes the oncogenic chimaeric protein, although the role of the reciprocal translocation partner (e.g. AF4-MLL) is currently under investigation [62] . The function of MLL partner genes in relation to the manifestation of disease is not well understood; indeed, a mouse MLL-LacZ fusion gene also causes leukaemia, suggesting that they are unlikely to play specific roles [63] . FMR2, however, is associated with FRAXE (fragile XE)-linked mental retardation, due to expansion of a CCG repeat upstream of the gene, although the functional significance of this is unclear [52, 64] . The knockout mouse is pathologically normal, yet it does exhibit subtle deficits in a learning and memory paradigm as well as enhanced long-term potentiation in the hippocampus [65] . The only member of this family present in D. melanogaster is Lilliputian (Lilli) that codes for a protein with 30-40 % identity with the C-terminus of the ALF proteins but does not contain an ALF domain [66, 67] . Studies of Lilli mutants demonstrated that this gene was required for correct cell growth and differentiation during embryogenesis and that it is also likely to co-ordinate a number of signal transduction pathways [66, 67] . A summary of these and additional findings related to the function of the ALF family is shown in Table 2 .
Some common themes have emerged from the analysis of models of ALF family dysfunction. Firstly, in all available mouse knockout models, some amount of pre-and post-natal death occurs; in Af4 null mice during the first 10 days, in Fmr2 knockouts at 3-9 months and in approx. 50 % of Af5q31 mutants in utero [51, 65, 68] . Secondly, approx. 20 % of the Af4 knockouts displayed a reduced overall size up to 6 weeks of age and smaller spleens and stomachs have been reported in the mice lacking Af5q31 [68] . At a cellular level, the Af4 knockout phenotype in the thymus was shown to be a caused by a defective expansion in the early stages of lymphocyte selection and in the fly, loss of lilli function causes an autonomous reduction in cell size, specifically suppressing excessive neuronal differentiation in response to a constitutively active form of Raf in the eye [66, 67] . Finally, there is a significant degree of overlap in the expression pattern of these genes in mouse. Although generally ubiquitously expressed in foetal stages, all are expressed in the embryonic and adult brain with both Af4 and Fmr2 predominantly expressed in Purkinje cells and the hippocampus [46, 65, 69] . Considering the degree of predicted functional overlap between ALF proteins, it is presumed that deficiency of one member can be partially compensated by the other; the analysis of compound double-knockouts will facilitate the study of this phenomenon. It is clear from the work to date that the ALF family is involved to some degree in cellular growth, supported by the small 
The role of Siah proteins in ALF protein family regulation
To understand how the robotic mutation might play a role in neurodegeneration, we investigated potential binding partners in the brain to determine if any proteins might exhibit a different affinity for wild-type or mutant Af4. Using a yeast two-hybrid system, the most frequently identified interactors were the E3 ubiquitin ligases Siah [Drosophila seven in abstentia (sina) homologues]-1a and Siah-2 [59] . The specificity of protein degradation by the ubiquitin-proteasome is controlled by the substrate recognition protein, referred to as an E3 ubiquitin ligase, which facilitates the transfer of ubiquitin to the target [70] . This regulatory mechanism is central to a wide range of signalling pathways, and Siah proteins have been shown to interact directly with many additional targets (summarized in [71] ). We have shown that in wildtype and robotic mice Siah-1a is expressed in Purkinje cells and that Af4 co-localizes with Siah-1a in the nucleus of non-neuronal (HEK-293T) and neuronal-like (P-19) cells by co-transfection studies. The interaction was also confirmed by co-immunoprecipitation from HEK-293T cells. Interestingly, a previous study had defined the minimal binding motif for Siah binding by aligning known interacting partners [72] . This simple Pro-XaaAla-Xaa-Val-Xaa-Pro amino acid motif (where Xaa is any amino acid) lay exactly over the position of the robotic mutation in Af4, so we predicted that Siah binding would be perturbed in mutants. We confirmed this using a quantitative in vitro binding assay, and showed that the affinity of Siah-1a for a robotic Af4 peptide was over 10-fold lower than one containing the wild-type sequence [59] . Considering the 100 % conservation of the Siah-binding motif in Fmr2 and overlapping expression with Af4, we also tested wild-type and mutant Fmr2 peptides. Once again, the affinity of the wild-type sequence was significantly greater than the mutant, suggesting that all members of the ALF family will be regulated by Siahmediated proteasomal degradation. Not only did our study describe a common regulatory mechanism linking ALF proteins, it provided an opportunity to demonstrate that this family of genes has overlapping functions in the brain. Pulse-chase experiments were used to quantify the relative degradation rates of Af4 by Siah proteins, demonstrating that the normally efficient turnover of mutant Af4 is reduced significantly in mammalian cells [59] . This suggests that in the robotic mouse an accumulation of mutant Af4 would result from a reduction in Siahmediated ubiquitination and its subsequent degradation.
Figure 2 Predicted mechanism leading to robotic mutant phenotype
In wild-type mice, Siah proteins facilitate the ubiquitinylation (Ub) and subsequent rapid degradation of Af4 by the proteasome. In robotic mice, mutant Af4 degradation is essentially abolished, leading to its accumulation. The mutant protein is then able to stabilize a multiprotein transcriptional activation (TA) complex, promoting transcription of downstream target genes ultimately leading to Purkinje cell death.
The consequences of this in the context of neuronal dysfunction are unclear at present; however, increased levels of Af4 could potentially facilitate the transactivation of downstream target genes (Figure 2) . The direct result of this could be investigated further by comparing the expression profiles of wild-type and robotic brain tissue using microarrays to identify clusters of genes that are co-regulated in a manner that reflects the pathology of the mutant. Although LAF4 has been shown to interact with DNA in a non-specific manner [53] , there is currently no evidence that Af4 binds to any specific DNA sequences. Therefore it is more likely that the levels of Af4 could influence the formation of a larger transactivation complex.
Some clues as to the content of such a complex come from the gene AF9. Despite not being directly related to the ALF family, this protein is also nuclear localized and is translocated to MLL in acute myeloid leukaemia [73] . A recent yeast two-hybrid study discovered that both AF4 and FMR2 interact with AF9, and that the AF9-binding domain is highly conserved throughout the ALF family [74] . The AF9-related proteins GAS41 and ENL have both been implicated as part of the SWI/SNF ATP-dependent chromatin remodelling complex. Consequently, additional members of this potentially large complex can be used to identify targets of Af4 transactivation. In the same study, overexpression experiments identified nuclear foci where AF4 is expressed and at which the interaction with AF9 takes place [74] . These 'AF4 bodies' did not colocalize with a panel of known nuclear proteins and the functional significance of this in vivo warrants further study.
Although robotic is not a direct model for any known human disease as yet, it will be interesting to determine whether mutations in Af4 can be found in one of the many inherited cerebellar ataxias that have no known genetic cause. Even if this finding is not forthcoming, Purkinje cell loss is a feature of many neurological disorders and this mutant is likely to shed light on new neurodegenerative pathways. The robotic mouse also illustrates the power of mutagenesis screens; complementing knockout strategies and as a consequence providing new and valuable functional information. Moreover, the discovery of a common regulatory pathway linking a family of transcription factors will allow us to understand more about the diverse nature of their normal function and contribution to mental retardation and leukaemia as well as neurodegeneration.
AN ALLELIC SERIES OF PERIPHERAL NEUROPATHY MUTANTS

Peripheral neuropathy
The flow of information between the CNS (central nervous system) and the periphery is mediated by peripheral nerves, with each axon surrounded by a myelin sheath [75] . This multi-lamellar structure is myelinated by Schwann cells, which wrap cytoplasmic processes around nerve axons. At the nodes of Ranvier, the point where two individual Schwann cell sheaths meet, the axolemma is exposed, increasing the velocity of nerve conductance by facilitating salutatory connections [76] . Consequently, degeneration of myelin leads to alterations in nerve conductance and ultimately motor defects. Peripheral demyelination can be caused by a number of factors, including inflammation [77] , although hereditary neuropathies are among the most common inherited neurological diseases. CMT1 (Charcot-MarieTooth disease type 1) is the most prevalent of these in humans and is caused by mutations in one of four genes; MPZ (myelin protein zero), GJB1 (gap junction protein connexin 32), EGR2 (early growth response 2 gene) or PMP22 (peripheral myelin protein 22) (reviewed in [78] ). In the case of PMP22, a range of known gene alterations leads to an array of phenotypes of varying severity. Duplication of a region on chromosome 17p11.2 containing PMP22 leads to the autosomal dominantly inherited CMT1A [79] , whereas one of over 30 known missense mutations cause CMT1-like syndrome or DSS (Dejerine-Sottas syndrome), a severe demyelinating neuropathy [80] . HNPP (hereditary neuropathy with liability to pressure palsies) is the least severe of these dominant disorders and is predominantly caused by a 
Pmp22
+/− -Tremor/some hypermyelination ++ single-copy deletion of the region duplicated in CMT1 [81] .
Modelling Pmp22 dysfunction in the mouse
Pmp22 is a small structural component of the nerve axon sheath, found within the lipid bilayers of compact myelin [82] . Its precise function is unclear; however, a mouse Pmp22 knockout shows severe demyelinating peripheral neuropathy suggesting a role in the early stages of myelination [83] . Consequently, a considerable number of in vitro studies have attempted to understand the normal role of Pmp22 [84] [85] [86] . However, it is the study of three spontaneous mutant lines, Tr (Trembler), Tr-J and Tr-Ncnp (Table 3 and Figure 3 ), that has helped to provide the most convincing explanation of the disease severity of Pmp22-related neuropathies in humans. These mice with point mutations appear to display an intermediate phenotype between the severely affected null mutants and those with one Pmp22 allele which exhibit a considerably milder phenotype [83] . This is consistent with the clinical observation that DSS patients with PMP22 point mutations exhibit a markedly more severe phenotype than HNPP patients with loss of one allele and suggests that the disease severity is not due to a simple loss-of-function effect [80] . Recently, investigations have concentrated on the propensity of mutant Pmp22 to form multimers, and the effect of mutations on intracellular trafficking, providing a hypothesis whereby expression of mutant Pmp22 causes retention of wildtype protein away from the membrane as an example of a dominant-negative effect [87] [88] [89] [90] [91] [92] [93] . However, analysis of compound heterozygotes suggests that in the mouse the Tr and Tr-J mutated protein has additional toxic gain-of-function properties [83] . Mouse mutants are undoubtedly providing a valuable tool for the modelling of peripheral neuropathies, although the differing genetic backgrounds of the Tr and Tr-J mice and human patients suffering from CMT1A or DSS render comparative studies relatively complex to decipher. Our own search for new neurological disease models led to the discovery of an allelic series of mutants on an identical genetic background, which has enabled further understanding of the role of protein aggregation in Pmp22-associated peripheral neuropathies.
Tr-m1H, -2H and -3H
Tr-m1H and Tr-m2H were one of the first mutant lines to be cloned from the Harwell ENU mutagenesis programme [94] . Both lines were identified by their small size at weaning, marked resting tremor and unusual hind limb grasping behaviour on tail suspension. Tr-m1H was the most severely affected line, suffering from intermittent fits in addition to exhibiting a more marked tremor. A third line, Tr-m3H, was later identified that displayed a strikingly similar although less severe phenotype than Tr-m1H and Tr-m2H (Table 3 ) [95] . Our standard histopathological screen of muscle, brain and spinal cord revealed no morphological abnormalities in the mutant lines; however, significant hypomyelination of the peripheral nerve was noted in all three cases. A reduction in myelin thickness and the number of axonal profiles was observed in mutants when compared with littermate controls in addition to an increase in Schwann cell numbers. Morphometric quantification demonstrated that the mean nerve fibre density and size reflected the degree of phenotypic severity of the three mutant lines, with Tr-m1H exhibiting the lowest values followed by Tr-m2H and Tr-m3H ( Figure 4 ). This order of severity was also indicated by the semi-quantitative SHIRPA scoring system, demonstrating the sensitivity of this behavioural testing protocol.
To identify the causative mutation, a genome scan on a small population of Tr-1H and Tr-2H 'speed-backcross' animals generated by in vitro fertilization was performed, generating a genetic map with a critical region on chromosome 11 of approx. 10 Mb. Although over 50 genes were present in this interval, the outstanding candidate gene was Pmp22 due to the obvious known link between mutations in this protein and peripheral neuropathy. Sequencing revealed point mutations in both lines distinct from the three previously identified spontaneous Pmp22 mouse mutants (Table 3 and Figure 3 ). Due to the similarity of the Tr-m3H phenotype to Tr-m1H and Tr-m2H, a genome scan was not deemed necessary and a third new mutation in Pmp22 was identified after confirmation of linkage to chromosome 11 using only a handful of flanking markers (Table 3 and Figure 3 ). These examples demonstrate the potential speed at which new mutants can be identified using a direct positional candidate approach, although it does rely on functional information about the known genes in the region of interest and their corresponding mutant or knockout phenotypes, which is not always readily available.
As new disease models, both Tr-m1H and Tr-m3H contain Pmp22 mutations in identical positions to patients with demyelinating neuropathy. With relevance to the Tr-m1H line, a His → Gln mutation at codon 12 has been reported in an individual suffering from DSS [96] . Possibly more significantly, Ser 72 that is altered in Tr-m3H is a putative hotspot for mutation in DSS; four mutations have now been described in eight patients suffering from this disease [80, [97] [98] [99] . Consequently, the conservative nature of the amino acid change in Tr-m3H compared with those reported in DSS patients may explain the relatively mild phenotype of this mutant line compared with the manifestation of a severe peripheral neuropathy in humans. This conservation between genotype and phenotype between mice and humans also applies to the spontaneous Tr mutants. The Pmp22-Tr mutation causes a severe tremor phenotype in mice [100] , and is in the same position as an amino acid altered in DSS patients [101] , whereas the less severe Tr-J mutation can be found in those suffering from the less serious disorder CMT1A [102] . However, despite the obvious clinical relevance of these models, how such mutations affect the function of PMP22 is still unclear.
In vitro modelling of Pmp22 aggregation
Although localization studies of mutant Pmp22 proteins have been carried out by others, the major advantage of analysing the Tr allelic series was that this particular aspect of the genotype-phenotype correlation could be investigated without any confounding background effects. Our transfection studies revealed that the severity of the phenotype was reflected in the propensity of the overexpressed protein to form aggregates. Wild-type Pmp22 was localized throughout the cytoplasm and at the plasma membrane, as reported previously [88] . Tr-m1H protein, however, was expressed in distinct perinuclear regions, and the presence of cytoplasmic aggregates was observed in the two less severe mutants with the largest multimers occurring in Tr-m3H [95] . To determine the likelihood of any dominant-negative effect, co-transfection studies were carried out with wild-type and mutant Pmp22. Cells expressing Tr-m2H or Tr-m3H only showed an occasional aggregate that stained for both wild-type and mutant protein, whereas a high degree of co-localization was observed in cells co-transfected with Tr-m1H constructs. In addition, by co-immunoprecipitation we confirmed that all three mutant proteins interact directly with wild-type Pmp22 and gel filtration chromatography showed that each of the mutant proteins form oligomers of a similar size, between 59 and 81 kDa [95] . Taken together, the evidence suggest that, although both wildtype and mutant Pmp22 proteins show a similar tendency to form high-molecular-mass oligomers in vitro, this is likely to occur to a greater extent in Tr-m1H due to the more significant degree of co-localization. Consequently, the sequestration of Tr-m2H and Tr-m3H protein into large aggregates would prevent this potentially toxic material reaching the membrane leading to a less severe phenotypic outcome.
It is known that the turnover of Pmp22 is relatively rapid, with over three-quarters of the newly-synthesized protein degraded in the ER (endoplasmic reticulum) [103] . To respond to the potential stress of protein overaccumulation, it has been suggested that ubiquitinylated cytoplasmic inclusions, or aggresomes, are formed [104] . The ubiquitination of such Pmp22 multimers may play a role in disruption of the myelin sheath directly, although in vitro studies have shown that potentially cytoprotective aggresomes form when wild-type Pmp22 is overexpressed [89, 93] . It is known that both the lysosomal and ubiquitin-proteasomal protein degradation systems are activated by mutant Pmp22 in mouse models and that aggresomes are themselves degraded by the lysosome, providing a mechanism whereby potentially harmful multimers are removed from the cell [105, 106] . It is therefore possible that these structures were observed in our Tr-m2H and Tr-m3H transfection studies, explaining reduced severity of these two mutant lines compared with Tr-m1H. The formation of cytoprotective intracellular protein aggregates is characteristic of a number of neurodegenerative disorders, including Parkinson's disease, and polyglutamine repeat disorders, such as Huntington's disease, and further evidence has emerged demonstrating that they are also cytoprotective [107, 108] . Whether similar pathological mechanisms exist for Pmp22-related peripheral neuropathies remains to be uncovered, but the access to an allelic series of mouse mutants has allowed us to gain valuable insight into the genotype-phenotype correlation between aggregate formation and disease severity.
CONCLUSIONS
There is no doubt that the mouse will continue to a play a vital role in the understanding of human gene function, although there is some debate over the most efficient approach to generate the more interesting and clinically relevant phenotypes [26] . Yet, it cannot always be assumed that the biological situation in humans can be modelled effectively by the corresponding mouse mutant, despite the obvious degree of gene conservation [109, 110] . For example, mutations in HEXA and HEXB cause the neurodegenerative disorders Tay-Sachs and Sandhoff's disease respectively. Hexb mutant mice displayed pathological features of the human condition, whereas no neurological disturbance was observed in Hexa mutants [111, 112] . Our work with the Harwell ENU screen highlights the two principal advantages of using a random approach to mutagenesis. Firstly, the discovery of a novel function for a known gene that could not have been predicted from the corresponding knockout, and secondly, the identification of an allelic series of mutants allowing comparative analysis of more than one functional component of a single gene. Indeed, ENU mutagenesis can generate the full range of allelic variants in a gene, including null, hypomorphic, dominant-negative and gain-of-function mutations, providing insights into gene function that would not be readily uncovered by gene targeting approaches. It is accepted that a combination of methods for the manipulation of the mouse genome, both random and directed, is most likely to provide a full complement of mutant genes. However, recent technological advances facilitating high-throughput phenotyping, gene-based screens and chromosomal manipulation will ensure that ENU mutagenesis continues to provide valuable models for neurological disease and ultimately new targets for drug discovery and validation.
